The first-ever treatment guidelines for Sjogren's syndrome have been issued. They include the use of rituximab for oral dryness, but a new U.K. study disputes this use for rituximab. (©WerayuthTes/Shutterstock.com)
U.K. Study Rejects Rituximab for Sjogren’s
A British study finds that rituximab is "neither clinically or cost-effective" in a study of patients with primary Sjogren’s syndrome who were being treated for fatigue and oral dryness.
New Sjogren's Guidelines Outline 19 Treatment Recommendations
The first-ever treatment guidelines for systemic Sjogren’s syndrome have been issued highlighting the need to alleviate symptoms, improve quality of life and prevent further damage.
New Classification Criteria for Sjogren's syndrome
The American College of Rheumatology and the European League Against Rheumatism have published an international set of classification criteria for primary Sjögren's syndrome.
Rheumatic IRAEs in Cancer Patients Treated with ICIs
The Rheumatology Journal Club resumes its Twitter chat series this week with a focus on rheumatological immune-related adverse events in immunotherapy.
Neurological Signs in Sjogren’s Too Often Ignored
Clinicians should pay more attention to neurological signs in patients with high-activity primary Sjogren’s Syndrome or those with prior neurological involvements.
Carbamylated Proteins as a Biomarker for Sjogren’s Syndrome
Autoantibodies against carbamylated proteins in Sjögren’s syndrome could be used as a new biomarker.
Sjögren’s Patients Could Benefit from Lupus Drug
B-cells that are active in lupus may also play a role in Sjögren’s syndrome. A new study finds that the same B-cell depleter drug, belimumab (Benlysta) approved for lupus, may also benefit Sjögren’s patients.
By clicking Accept, you agree to become a member of the UBM Medica Community.